Personalis Shares Surge on $12M Tempus Deal to Co-Commercialize NeXT Personal Dx

Introduction

Personalis Inc (NASDAQ: PSNL) is a precision oncology company headquartered in Fremont, California. Its share price closed at $9.53 on November 10, 2025, reflecting a 37.52% increase on a trading volume of 1,016,683 shares. The company develops genomic assays designed to detect minimal residual disease (MRD) and guide targeted therapies throughout the cancer patient journey.

Corporate Structure

Personalis employs teams across genomics, bioinformatics, and clinical operations. The executive leadership includes Chris Hall (President & CEO) and Dr. Richard Chen (EVP of R&D & Chief Medical Officer). Key clinical contacts listed on ClinVar include Sarah Garcia, Joshua Anderson, Erin Ayash, and Heather Wetzel. The company’s laboratory and R&D functions operate from its Fremont facility, supported by proprietary algorithms for tumor and normal profiling.

Liquid biopsy by Pawel Czerwinski

Recent Developments

In October 2025, Personalis launched NeXT Personal® Dx, a whole-genome liquid biopsy laboratory-developed test (LDT) for MRD detection and cancer recurrence monitoring. On November 10, 2025, Personalis and Tempus announced a strategic collaboration to co-commercialize NeXT Personal Dx. Under the exclusive agreement for tumor-informed MRD testing in lung cancer—and later for breast cancer and immunotherapy monitoring—Tempus will:

• Provide up to $12 million in milestone-based funding for clinical evidence development.
• Integrate NeXT Personal Dx into its testing menu.
• Utilize its oncology sales force to enhance market access.

Personalis will process and bill the tests, drive reimbursement, complete clinical validation for the new indications, and issue warrants allowing Tempus to purchase up to 9.2 million common shares over 24 months. Personalis continues to engage in MRD education initiatives, featuring discussions led by Amal Thommil and Dr. Chen on the clinical implications of MRD technologies.

Financial and Strategic Analysis

The stock’s 37.52% gain on November 10, 2025, may reflect investor response to the collaboration with Tempus and the potential testing of tens of thousands of patients over three years. The $12 million in funding may alleviate some of the R&D financial pressures for Personalis, while the warrant issuance could lead to equity dilution. An 8-K filed on November 10, 2025, provides formal disclosure of the collaboration; a 10-Q filed on November 4, 2025, outlines financial metrics and standard biotech risk factors, including regulatory approvals and market competition. The partnership aligns with Personalis’ strategy to advance MRD testing and enhance market integration.

Market Position and Industry Context

Personalis operates in the MRD and liquid biopsy sector, where sensitivity and specificity are important differentiators. NeXT Personal Dx’s tumor-informed approach may provide advantages over tumor-naïve assays in early detection of recurrence. The partnership with Tempus, known for its multimodal data and AI analytics capabilities, could enhance Personalis’ market implementation. As oncology care increasingly emphasizes personalized monitoring and real-time treatment adaptations, collaborations between genomics firms and AI platforms appear to be emerging trends in the industry.

tl;dr

On November 10, 2025, Personalis Inc’s stock increased by 37.52% following the announcement of an exclusive collaboration with Tempus to co-commercialize its NeXT Personal Dx MRD test. The agreement includes up to $12 million in funding, integration into Tempus’ testing menu, and warrants for 9.2 million shares. Clinical validation for breast cancer and immunotherapy monitoring is planned after initial lung cancer testing, with the aim of screening tens of thousands of patients over the next three years. Future funding milestones may broaden market access through Tempus’ oncology sales network.